Research reveals that PPARα agonists do not promote biogenesis in human peroxisomes, suggesting alternative pathways for therapeutic intervention.
Peroxisome biogenesis in humans is not governed by PPARα, overturning a paradigm established in rodents. PPARα agonists fail to induce canonical peroxisomal genes, and functional response elements are absent from key promoters. Human peroxisomes nonetheless expand through PPAR-independent pathways, positioning them as organelles tuned to immunometabolic and redox demands and redefining strategies for therapeutic intervention.
No takes yet. Share an insight, caveat, or question.
Mast et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: